Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Drug

Humanwell Healthcare Receives NMPA Approval for HW241045 IPF Clinical Trials

Fineline Cube Aug 6, 2025

China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation...

Company Drug

Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy

Fineline Cube Aug 6, 2025

China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...

Company Drug

CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted

Fineline Cube Aug 6, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...

Company Drug

Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China

Fineline Cube Aug 6, 2025

Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...

Company Deals

ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D

Fineline Cube Aug 5, 2025

Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...

Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Medical Device

Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu

Fineline Cube Aug 5, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...

Company Drug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Fineline Cube Aug 5, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...

Company Drug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Fineline Cube Aug 5, 2025

China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...

Company Deals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Fineline Cube Aug 5, 2025

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...

Company Drug

Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials

Fineline Cube Aug 5, 2025

China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...

Company Deals

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments

Fineline Cube Aug 4, 2025

Korean AI drug discovery company Dr. Noah Biotech has announced the initiation of discussions with...

Company Deals

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board

Fineline Cube Aug 4, 2025

China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...

Company Drug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) has completed its investigation into the death of...

Company Drug

Mabwell’s CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US

Fineline Cube Aug 4, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment

Fineline Cube Aug 4, 2025

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) announced today that its CU-40102 (finasteride topical spray)...

Company Drug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

Fineline Cube Aug 4, 2025

China-based cell therapy biotech UTC Therapeutics announced receiving clearance from the US Food and Drug...

Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Posts pagination

1 … 142 143 144 … 689

Recent updates

  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
  • Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China
  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Others

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.